Skip to main content
SpringerLink
Log in

Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases

  • Original article
  • Published:
Journal of Hepato-Biliary-Pancreatic Sciences

Abstract

Background

The role of adjuvant chemotherapy for stage IV colorectal cancer has so far been under-investigated. The aim of this study was to assess the feasibility and short-term outcome of adjuvant chemotherapy with the FOLFOX regimen following liver resection for patients with colorectal liver metastasis (CRLM).

Methods

From May 2005 to September 2010, 86 patients with CRLM underwent hepatic resection in the Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University. Of these patients, 24 received FOLFOX4 or modified FOLFOX6 as postoperative adjuvant chemotherapy.

Results

Nineteen male and 5 female patients received adjuvant chemotherapy following liver resection. Twenty-one (87.5 %) of these patients completed 6 cycles of adjuvant chemotherapy. Five patients required a dose reduction due to neutropenia, and the dose intensities of oxaliplatin and 5-FU were 93.6 and 94.1 %, respectively. There were no severe adverse events from the treatments. The median follow-up period was 48.4 months. Recurrences developed in 12 patients, and 3 patients died during the follow-up period. The 3- and 5-year disease-free survival and overall survival were 51.6 and 45.1 % and 95.5 and 76.0 %, respectively.

Conclusions

Adjuvant FOLFOX is feasible and might provide a good prognosis for CRLM patients who undergo liver resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

CRLM:

Colorectal liver metastases

OS:

Overall survival

DFS:

Disease-free survival

FOLFOX:

Chemotherapy with oxaliplatin plus 5-fluorouracil and leucovorin

FOLFIRI:

Chemotherapy with irinotecan plus 5-fluorouracil and leucovorin

AE:

Adverse event

References

  1. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306(6880):752–5.

    Article  PubMed  CAS  Google Scholar 

  2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(1):23–30. doi:10.1200/JCO.2004.09.046.

    Article  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. doi:10.1056/NEJMoa032691.

    Article  PubMed  CAS  Google Scholar 

  4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):2013–9. doi:10.1200/JCO.2007.14.9930.

    Article  CAS  Google Scholar 

  5. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(5):663–71. doi:10.1200/JCO.2008.20.8397.

    Article  CAS  Google Scholar 

  6. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 18–21.

    Google Scholar 

  7. Curley SA. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol. 2005;32(6 Suppl 9):S109–11. doi:10.1053/j.seminoncol.2005.06.011.

    Article  PubMed  Google Scholar 

  8. Kokudo N, Imamura H, Sugawara Y, Sakamoto Y, Yamamoto J, Seki M, et al. Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg. 2004;11(2):84–91. doi:10.1007/s00534-002-0754-2.

    Article  PubMed  Google Scholar 

  9. Belli G, D’Agostino A, Ciciliano F, Fantini C, Russolillo N, Belli A. Liver resection for hepatic metastases: 15 years of experience. J Hepatobiliary Pancreat Surg. 2002;9(5):607–13. doi:10.1007/s005340200082.

    Article  PubMed  Google Scholar 

  10. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(16):2198–204. doi:10.1200/JCO.2006.08.2974.

    Article  CAS  Google Scholar 

  11. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(6):872–7. doi:10.1200/JCO.2008.19.5362.

    Article  Google Scholar 

  12. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(19):3109–16. doi:10.1200/JCO.2008.20.6771.

    Article  CAS  Google Scholar 

  13. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(31):4976–82. doi:10.1200/JCO.2006.06.8353.

    Article  CAS  Google Scholar 

  14. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(30):4906–11. doi:10.1200/JCO.2008.17.3781.

    Article  CAS  Google Scholar 

  15. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. doi:10.1016/S0140-6736(08)60455-9.

    Article  PubMed  CAS  Google Scholar 

  16. Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, et al. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res. 2010;30(3):1015–20.

    PubMed  CAS  Google Scholar 

  17. Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, et al. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol Jpn Soc Clin Oncol. 2010;15(3):263–70. doi:10.1007/s10147-010-0046-9.

    Article  Google Scholar 

  18. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(13):2065–72. doi:10.1200/JCO.2005.05.3074.

    Article  CAS  Google Scholar 

  19. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24. doi:10.1097/SLA.0b013e31815774de.

    Article  PubMed  Google Scholar 

  20. Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, et al. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012;19(1):72–84. doi:10.1007/s00534-011-0460-z.

    Article  PubMed  Google Scholar 

  21. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. doi:10.1056/NEJMoa032709.

    Article  PubMed  CAS  Google Scholar 

  22. Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, et al. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 2009;39(6):406–9. doi:10.1093/jjco/hyp035.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

No conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Yasuo Sakamoto, Toru Beppu, Yuji Miyamoto, Hirohisa Okabe, Satoshi Ida, Katsunori Imai, Akira Chikamoto, Masayuki Watanabe, Hiroshi Takamori & Hideo Baba

  2. Department of Multidisciplinary Treatment for Gastroenterological Cancer, Kumamoto University Hospital, Kumamoto, Japan

    Yasuo Sakamoto & Toru Beppu

Authors
  1. Yasuo Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toru Beppu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuji Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirohisa Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Ida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsunori Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Chikamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayuki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroshi Takamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba.

About this article

Cite this article

Sakamoto, Y., Beppu, T., Miyamoto, Y. et al. Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases. J Hepatobiliary Pancreat Sci 20, 307–312 (2013). https://doi.org/10.1007/s00534-012-0523-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-012-0523-9

Keywords

Search

Navigation